Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16539040 | 0.95 | GLP1R (0.44) | GLP1REPHX2TSHRTLR2TLR1 | |
| SCHEMBL16538986 | 0.94 | GLP1R (0.47) | GLP1REPHX2TSHRTLR2TLR1 | |
| SCHEMBL29902232 | 0.91 | GLP1R (0.50) | GLP1REPHX2TSHRTLR2TLR1 | |
| SCHEMBL29902274 | 0.91 | GLP1R (0.50) | GLP1REPHX2TSHRTLR2TLR1 | |
| SCHEMBL16539021 | 0.91 | GLP1R (0.49) | GLP1REPHX2TSHRTLR2TLR1 | |
| SCHEMBL1509898 | 0.91 | EPHX2 (0.43) | GLP1REPHX2TSHRTLR2TLR1 | |
| SCHEMBL1509858 | 0.91 | EPHX2 (0.43) | GLP1REPHX2TSHRTLR2TLR1 | |
| SCHEMBL16538712 | 0.91 | EPHX2 (0.43) | GLP1REPHX2TSHRTLR2TLR1 | |
| SCHEMBL25530751 | 0.90 | TSHR (0.44) | GLP1REPHX2TSHRTLR2TLR1 | |
| SCHEMBL1509891 | 0.88 | EPHX2 (0.43) | EPHX2TSHRTLR2TLR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | GLP1R 11/4885EPHX2 2213/4885TSHR 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.